Aneuscreen
Decision-support System for the Early Detection of Brain Aneurysms
Company Overview
Snapshot
Founded in June 2017 by Assaf Harel and Haim Ezer, Aneuscreen operates with 1–10 employees. The company has secured capital across two funding rounds, with investor Chaim Chizik participating in a Seed round in August 2020.
Business overview
Aneuscreen is a Health Tech & Life Sciences company focused on developing a decision-support system for the early detection of brain aneurysms. The company utilizes advanced computer vision and AI techniques to provide a highly accurate diagnostic exam capable of predicting future aneurysm formation and detecting existing aneurysms, even those under 4mm that radiologists might miss. This solution aims to save lives by preventing severe outcomes from rupture events, such as Subarachnoid hemorrhage (SAH), while reducing associated economic burdens. Aneuscreen's technology functions as both a detection tool and a classifier for identifying individuals susceptible to aneurysm development based on arterial tree morphology analysis, and it can be integrated with various neuroimaging modalities. The company serves markets in Europe and the United States, targeting healthcare providers and insurance companies.
Log in to access full profile ›Company Intelligence Q&A
- What is Aneuscreen's primary focus?
- Aneuscreen develops a decision-support system for the early detection of brain aneurysms, utilizing advanced computer vision and AI techniques to predict future formations and detect existing aneurysms.
- Who founded Aneuscreen?
- Aneuscreen was founded by Assaf Harel and Haim Ezer in June 2017.
- What technology does Aneuscreen utilize?
- Aneuscreen's solution incorporates advanced computer vision and artificial intelligence, including deep learning and image recognition, for morphology analysis of the brain's arterial tree.
- What markets does Aneuscreen target?
- Aneuscreen targets the European and United States markets, serving healthcare providers and insurance companies.